Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Microbot Medical ( (MBOT) ) has issued an announcement.
On November 5, 2025, Microbot Medical announced the limited commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. This initial market release targets high procedure volume regions with preliminary demand and aims to gather real-world insights to guide a full market release in April 2026. The company has completed necessary infrastructure preparations, including hiring a core commercial team and establishing a logistics partnership, to support this launch.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety.
Average Trading Volume: 4,342,429
Technical Sentiment Signal: Sell
Current Market Cap: $135.7M
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.